Teva Pharmaceuticals Reports Positive Trial Results for Celiac Disease Drug
Translated & summarized from NEWSru Israel by baba
Teva Pharmaceuticals has announced positive results from trials of its experimental celiac disease drug, tev-408, which significantly reduced intestinal damage after gluten exposure. The drug targets the IL-15 protein and is also being studied for vitiligo treatment.
The story in 6 lines · by baba
- Teva's experimental celiac drug tev-408 showed positive trial results.
- The drug significantly reduced intestinal damage from gluten exposure.
- Fifty adult celiac patients participated in the trial.
- Tev-408 targets the IL-15 protein involved in inflammation.
- Teva's stock rose nearly 2% on the news.
- Currently, a gluten-free diet is the main treatment for celiac disease.
Israeli pharmaceutical giant Teva announced successful trial results for its experimental celiac disease treatment, tev-408. The company stated that the drug significantly reduced intestinal damage in patients exposed to gluten during the study. The trial involved 50 adult celiac patients. Tev-408 functions as an antibody that targets and blocks the IL-15 protein, which is implicated in inflammatory and immune responses. Teva is also investigating the drug's potential for treating vitiligo. Israeli public broadcaster Kan Bet noted that there is currently no approved drug treatment for celiac disease, with a gluten-free diet remaining the primary management strategy. Following the announcement of the trial results, Teva's stock price increased by nearly 2%.
